Related references
Note: Only part of the references are listed.Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer.
Ramaprasad Srinivasan et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor
Renaud Grepin et al.
THERANOSTICS (2020)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients
Yeonjoo Choi et al.
CANCER RESEARCH AND TREATMENT (2019)
Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis
Bin Zou et al.
BMC BIOINFORMATICS (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma
Daniel S. W. Tan et al.
NATURE MEDICINE (2017)
Mechanism based targeted therapy for hereditary leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinib
R. Srinivasan et al.
EUROPEAN JOURNAL OF CANCER (2014)
Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy
J. J. Wheler et al.
ANNALS OF ONCOLOGY (2013)
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Phase II Study of Erlotinib in Patients With Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer: SWOG S0317
Michael S. Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma:: A randomized phase III clinical trial
Alain Ravaud et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer
Ronald M. Bukowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis
R. M. Bukowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma
William G. Kaelin
CLINICAL CANCER RESEARCH (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma
M Jermann et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib
JD Hainsworth et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients
T Sakaeda et al.
PHARMACEUTICAL RESEARCH (2005)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer
K Smith et al.
CANCER RESEARCH (2005)
Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer
EK Rowinsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma
NA Dawson et al.
CLINICAL CANCER RESEARCH (2004)
Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1α expression in renal cell carcinomas
X Na et al.
JOURNAL OF UROLOGY (2003)
Phase II trial of ZD1839 (IRESSA™) in patients with advanced renal cell carcinoma
B Drucker et al.
INVESTIGATIONAL NEW DRUGS (2003)
Share Paper
